Context Therapeutics, Inc. (CNTX)

Context Therapeutics' stock price has increased by 61.9% since January 1, 2026. CTIM-76 received FDA Fast Track Designation for platinum-resistant ovarian cancer on April 2, 2026. The company reported a net loss of $8.7 million in Q1 2026, with cash reserves expected to last into mid-2027. Phase 1a interim clinical data for CTIM-76 is expected in June 2026 and for CT-95 in September 2026. A Phase 1 clinical trial for CT-202 is expected to begin in Q3 2026, following regulatory approvals in Australia. The company presented at several healthcare conferences in March 2026. In May 2024, Context Therapeutics announced a private placement expected to generate $100.0 million, extending its cash runway into 2028.

Context Therapeutics does not experience traditional product demand seasonality as a clinical-stage biopharmaceutical company without commercialized products. Revenue comes from capital raises and interest on cash reserves. However, stock price data suggests potential seasonality in stock returns, with May and June showing higher probabilities of positive returns.

Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing T cell engaging bispecific antibodies for solid tumor treatment. Their pipeline includes CTIM-76, a Claudin 6 x CD3 bispecific antibody for CLDN6-positive tumors; CT-95, a Mesothelin x CD3 TCE bispecific antibody; and CT-202, a Nectin-4 x CD3 TCE bispecific antibody. The company currently generates no product revenue and is supported by capital raises and interest income.

Context Therapeutics, Inc. is headquartered in Philadelphia, Pennsylvania, United States.

Context Therapeutics has a generally positive brand reputation due to clinical advancements and analyst sentiment. The company has a consensus rating of "Moderate Buy" with an average rating score of 2.88. Analysts have increased price targets for CNTX, with a consensus price target of $6.60. Key events contributing to its reputation include receiving FDA Fast Track Designation for CTIM-76, presenting preclinical data at scientific conferences, and regularly reporting financial results and pipeline progress. There have been no explicitly reported events negatively impacting Context Therapeutics' reputation in the past year.

Context Therapeutics Inc. is primarily owned by institutional shareholders (70.98%), followed by retail investors (27.59%) and insiders (1.43%). Major institutional owners include MPM BioImpact LLC, Blue Owl Capital Holdings LP, and Deep Track Capital, LP. Martin A. Lehr, the CEO, is the largest individual shareholder, owning 1.18% of the company.